Welcome to our dedicated page for Quoin Pharmaceuticals news (Ticker: QNRX), a resource for investors and traders seeking the latest updates and insights on Quoin Pharmaceuticals stock.
Quoin Pharmaceuticals Ltd (QNRX) is a clinical-stage biopharmaceutical company pioneering therapies for rare dermatological disorders and orphan diseases. This dedicated news hub provides investors and healthcare professionals with timely updates on regulatory milestones, clinical trial progress, and strategic partnerships central to advancing treatments for conditions like Netherton Syndrome and Epidermolysis Bullosa.
Access authoritative information on Quoin's therapeutic pipeline developments, including FDA designations and international trial expansions. The page consolidates official press releases, research collaborations, and manufacturing updates while maintaining strict compliance with financial disclosure standards.
Key content areas include phase trial results, intellectual property announcements, and partnership agreements with biotechnology innovators. All materials are curated to support informed decision-making without speculative commentary or investment recommendations.
Bookmark this page for streamlined tracking of Quoin's progress in addressing unmet medical needs through targeted drug development programs and evidence-based research initiatives.
Quoin Pharmaceuticals Ltd. has opened three clinical sites for its study of QRX003, a treatment for Netherton Syndrome, a rare skin condition. The double-blind, placebo-controlled trial began in June 2022 and aims to recruit patients across six sites in the US, with the remaining three expected to open soon. QRX003, if approved, could be the first treatment for this condition. Quoin plans to self-commercialize QRX003 and has formed marketing partnerships in 60 countries, enabling potential early access.
Quoin Pharmaceuticals Ltd. (QNRX) initiated a clinical trial for its lead product QRX003, aimed at treating Netherton Syndrome, and expanded its global partnerships to eight across 60 countries. The company closed a $16.8 million public offering, netting approximately $15 million. Despite a net loss of $2.7 million for Q2 2022, Quoin regained compliance with Nasdaq's listing requirements concerning stockholders’ equity and minimum bid price. Significant progress includes a research agreement with Queensland University of Technology for scleroderma treatment.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that it will report its second quarter 2022 financial results on August 18, 2022, prior to market open. Management will host a webcast and conference call at 8:30 a.m. ET the same day to discuss the results and provide a corporate update. The live call can be accessed via specific domestic and international dialing codes, and the archived webcast will be available on the company's website. Quoin focuses on developing therapeutic products for rare and orphan diseases, with a pipeline targeting multiple indications.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has closed its public offering of 11,050,000,000 ordinary shares, which equates to 2,210,000 American Depositary Shares (ADS) at $5.00 per ADS, alongside pre-funded warrants for 5,750,000,000 ordinary shares at $4.9999 each, generating $16.8 million in gross proceeds. The net proceeds will be utilized for general corporate purposes. The offering was facilitated by A.G.P./Alliance Global Partners, and the registration statement was approved by the SEC on August 5, 2022.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has priced a public offering of 2,210,000 American Depositary Shares (ADS) representing 11,050,000,000 ordinary shares at $5.00 per ADS, along with pre-funded warrants for 1,150,000 ADS at $4.9999 each. The total gross proceeds from the offering are expected to be $16.8 million, closing around August 9, 2022. Proceeds will be utilized for general corporate purposes. A.G.P./Alliance Global Partners is the sole placement agent for this offering, which follows an effective registration statement filed with the SEC.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that it received significant Scientific Advice from the European Medicines Agency (EMA) regarding its product, QRX003, for treating Netherton Syndrome. This guidance, delivered sooner than expected, will enhance the clinical development plan in both the US and Europe. Currently in a clinical study in the US, QRX003 aims to improve the skin barrier for Netherton patients. The company has also expanded its distribution network to 60 countries, emphasizing accessibility for patients post-approval.
Quoin Pharmaceuticals (NASDAQ: QNRX) has signed a License and Distribution Agreement with Endo Ventures, an affiliate of Endo International for its lead product, QRX003, aimed at treating Netherton Syndrome, in Canada. Paladin Labs, a subsidiary of Endo, will handle commercialization upon regulatory approval. This marks Quoin’s eighth agreement for QRX003, expanding its market presence to 60 countries. CEO Dr. Michael Myers expressed optimism about the partnership's potential to enhance patient access to Quoin's products once approved.
Endo International plc (NASDAQ: ENDP) announced a collaboration with Quoin Pharmaceuticals Inc. (NASDAQ: QNRX) to develop and commercialize QRX003 for treating Netherton syndrome in Canada. This skin disorder, caused by a mutation in the SPINK5 gene, currently lacks effective treatment options. If approved, Paladin Labs, a subsidiary of Endo, will manage all commercial activities in Canada, aiming for a product launch in 2025. This partnership underscores Endo's focus on addressing unmet medical needs in rare diseases.
Quoin Pharmaceuticals Ltd. has initiated its first clinical site for the QRX003 study, aimed at treating Netherton Syndrome, a rare genetic disorder. The randomized, double-blind, vehicle-controlled study will test two doses of QRX003 over a twelve-week period. With FDA discussions in progress, various clinical endpoints will be evaluated. The company aims to improve skin barrier function and patient quality of life. Quoin has already formed partnerships in 60 countries for potential market access post-approval, enhancing its global reach.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) received a notification from Nasdaq on June 10, 2022, indicating non-compliance with the minimum bid price requirement of $1.00 per share, necessitating corrective action within 180 days. This notification does not currently affect its Nasdaq listing. The company is also addressing earlier non-compliance regarding stockholders’ equity, having submitted a plan to Nasdaq for resolution. While the company remains operationally unaffected, the prospect of delisting poses a significant risk to shareholders.
FAQ
What is the current stock price of Quoin Pharmaceuticals (QNRX)?
What is the market cap of Quoin Pharmaceuticals (QNRX)?
